CONTEXT: The introduction of novel imaging modalities has increased the detection of @entity263 ( @entity263 ) recurrence, potentially justifying the use of a @entity3 ( @entity3 ) with surgery or radiotherapy (RT) rather than a systemic approach. OBJECTIVE: To perform a systematic review of @entity3 for oligometastatic @entity263 recurrence. EVIDENCE ACQUISITION: This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We searched the Medline and Embase databases from 1946 to February 2014 for studies reporting on biochemical or clinical progression and/or @entity137 or complications of @entity3 (RT or surgery). Reports were excluded if these end points could not be ascertained or separately analysed, or if insufficient details were provided. Methodological quality was assessed using an 18-item validated quality appraisal tool for case series. EVIDENCE SYNTHESIS: Fifteen single-arm case series reporting on a total of 450 @entity1 met the inclusion criteria. Seven studies were considered of acceptable quality. Oligometastatic @entity263 recurrence was diagnosed with positron emission tomography with coregistered computed tomography in most of the @entity1 (98%). Nodal, bone, and visceral metastases were treated in 78%, 21%, and 1%, respectively. @entity1 were treated with either RT (66%) or lymph node dissection (LND) (34%). Adjuvant @entity342 deprivation was given in 61% of @entity1 (n=275). In the case of nodal metastases, prophylactic nodal irradiation was administered in 49% of @entity1 (n=172). Overall, 51% of @entity1 were progression free 1-3 yr after salvage @entity3 , with most of them receiving adjuvant treatment. For RT, grade 2 @entity137 was observed in 8.5% of @entity1 , with one case of grade 3 @entity137 . In the case of LND, 11% and 12% of grade 2 and grade 3 complications, respectively, were reported. CONCLUSIONS: @entity3 is a promising approach for oligometastatic @entity263 recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care. @entity1 SUMMARY: We performed a systematic review to assess complications and outcomes of treating @entity263 recurrence with surgery or radiotherapy. We concluded that although this approach is promising, it requires validation in randomised controlled trials.

@entity3 -directed Therapy of Regional and Distant Recurrences After Curative Treatment of XXXX : A Systematic Review of the Literature.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENT'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['oligometastatic prostate cancer', 'PCa'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis-directed therapy', 'MDT']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
